Meeting
2020 ASCO Virtual Scientific Program
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Authors
Julia Foldi
Yale Cancer Center, New Haven, CT
Julia Foldi , Catherine A. Schnabel , Max Salganik , Lajos Pusztai , Tara B. Sanft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 527)
DOI
10.1200/JCO.2020.38.15_suppl.527
Abstract #
527
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis.
First Author: Elise Deluche
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2013 ASCO Annual Meeting
Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.
First Author: Yi Zhang
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li